The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

DelveInsight’s, “Metastatic Prostate Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in metastatic prostate cancer pipeline landscape. It ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Sydney-based Clarity Pharmaceuticals has received a third fast track designation (FTD) from the US Food and Drug ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Miguel Muniz discussing outcomes for 177 Lu-PSMA-617 with and without concurrent use of androgen receptor pathway ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...